Doomed to extraordinary turning and leaping -- the 27th national pharmaceutical economic information conference was held ceremoniously

Source: medical economics Daily, October 28-29, 2015, is destined to be extraordinary The Fifth Plenary Session of the 18th Central Committee of the Communist Party of China is being held in Beijing, and the representatives have jointly drawn up a new blueprint for China's economic and social development in the next five years The 27th national pharmaceutical economic information conference hosted by CFDA Southern pharmaceutical Economic Research Institute was held in Taizhou, Jiangsu Province, which is a famous historical and cultural city, by the Bank of Tiande lake The elites of the national pharmaceutical industry gathered together to discuss the transformation and upgrading path of the pharmaceutical industry under the new normal China's economy is faced with enormous pressure from the old to the new How to plan the development of the next five years with quality is particularly important In this context, the 27th national pharmaceutical economic information conference is themed with "great turning point of medicine, dream building, the 13th five year plan" - developing new energy of industry ", aiming to explore the development path of transformation and upgrading of pharmaceutical industry in the 13th five year plan During the meeting, there were 18 special reports and 5 parallel meetings, which respectively elaborated and predicted the drug regulation and industrial development from the modules of industrial policy, macroeconomic and industrial structure adjustment, new policies of drug supervision at home and abroad, and medical marketing under the new situation Wu Zhen, deputy director of the State Food and drug administration, attended the conference and made a keynote report Zhang Wenzhou, former deputy director of the State Food and drug administration, director of the editorial board of the pharmaceutical economic daily, Bian Zhenjia, former party member of the State Food and drug administration, Hu Xiaoshu, director of the Jiangsu food and drug administration, LAN Shaomin, Secretary of the Taizhou Municipal Party committee and director of the Standing Committee of the Municipal People's Congress of Jiangsu Province, Zhang Zhijun, vice president of the China food and drug inspection and Research Institute, and China Pharmaceutical Association Zhang Yaohua, chairman, Lu Chunyun, member of the Standing Committee of Taizhou Municipal Committee and Secretary of the Party Working Committee of the pharmaceutical high tech Zone, and fan Ling, vice mayor of Taizhou Municipal People's government, attended the event The opening ceremony of the conference was presided over by Tao Jianhong, deputy director of CFDA South Institute of pharmaceutical economics and editor in chief of pharmaceutical economics In addition, this year marks the 35th anniversary of the founding of pharmaceutical economic news As a professional media that has witnessed the development track of modern pharmaceutical industry, the conference also held a special ceremony to celebrate the 35th anniversary of pharmaceutical economic news - the advocacy ceremony of industrial social responsibility Reporters noted that the conference attracted more than 1000 representatives from the national mainstream pharmaceutical enterprises and top 100 retail chains As Tao Jianhong said in his opening speech, "China's economy has entered a new journey." In the 13th five year plan, transformation of economic development mode, promotion of innovation driven development, reform of system and mechanism are closely related to the development of the pharmaceutical industry From the perspective of China's regulatory policies, the verification of clinical data, the clearing up of the backlog of review, and the pilot of the listing permit holder system are all in the right direction for China's drug innovation With the introduction of a series of new policies, there will be a new pattern of drug research and development in China However, the path of transformation and upgrading is not achieved overnight, only innovation is the constant main line " At the meeting, on the topic of how to innovate, when Wu Zhen made a theme report, he focused on the problem of clinical data self-examination and verification He stressed that "only when the self-examination and verification of clinical trial data are in place can the untrue and imperfect application in the registration application be eliminated, and innovation be truly encouraged." On the contrary, the phenomenon of falsification of clinical trial data will become more and more serious Therefore, CFDA's attitude is very clear, and there is no exception that every audit must be checked " Wu Zhen stressed that "the door that allows enterprises to withdraw by themselves is always open, but for those enterprises that do not want to withdraw automatically, one should be severely punished if one is found Bring the biggest regulatory effect with the smallest administrative cost To encourage enterprises to do well in medicine is to take solving clinical needs as the core " He believes that the truth and reliability of drug research and development data is the basic bottom line of good medicine, and only in this way can enterprises that are really good at medicine be elated The next five years will be the key to the transformation of the pharmaceutical industry from a pharmaceutical power to a pharmaceutical power How to achieve this goal depends on how to draw the road map In this strategy, the improvement of the internal quality of generic drugs is a key link At the meeting, Zhang Zhijun summarized and analyzed the key points for the implementation of quality consistency evaluation of generic drugs in China He disclosed that at present, there are some practical problems in the conformity evaluation of generic drugs, especially the difficulty in the in vitro evaluation method of domestic reference preparations, followed by the big difference in product approval documents How to improve the quality of generic drugs, which is consistent with the quality and efficacy of the original research drugs“ We will carry out the consistency evaluation by stages and batches The enterprise is the main body of the consistency evaluation, and it is required that the consistency evaluation should be completed within the specified time limit " At the meeting, Lin Jianning, director of CFDA South pharmaceutical Economic Research Institute, pointed out in the theme report that the current pharmaceutical economic growth is further slowing down He analyzed the variables and relief ideas existing in the current pharmaceutical economic development from multiple perspectives "During the 13th Five Year Plan period, the development of the pharmaceutical economy should not be expected to return to the original ultra-high growth, but the medium to high growth can still be expected The first two years are relatively severe, and the next three years are expected to recover; the characteristics of the sunrise industry in the pharmaceutical industry will not change " Lin Jianning suggested that "in the near future, the key to 2016 is for pharmaceutical enterprises to pay attention to profit and cash flow; in the long run, enterprises should take the initiative to transform and upgrade, take the road of attaching importance to quality, management and innovation." Zong Yungang, deputy director of CFDA South Institute of pharmaceutical economics, analyzed the relationship between drug approval and market supply and demand in China He pointed out that "at present, China's drug registration approval number is excessively repeated, the utilization rate of approval documents is generally low, and the market share of the top ten approval documents in sales volume is relatively high Our judgment is that the supply and demand relationship of drugs is basically that supply exceeds demand, especially for large varieties and generic varieties." So, how to find the contact point between policy and economic slow cycle? To be stronger and bigger is the real expression of the mainstream industry enterprises With regard to the new normal topic in the turning era of Chinese medicine, Guangyao group, Huabei pharmaceutical, Harbin Pharmaceutical Group, step pharmaceutical, Tianshili group, Yuheng pharmaceutical, sunflower pharmaceutical, Xiansheng pharmaceutical, Tianpu pharmaceutical and other industry leaders have a heated discussion in the TV Forum Gong Zhaolong, a former senior FDA drug review expert and national "Thousand Talents Program" expert, analyzed the adjustment of FDA drug review ideas and the new thinking of China's R & D from an international perspective In addition, Lu Chunyun introduced the future development trend of China's pharmaceutical industry park; Zhang Buyong, general manager of punctuation information · minenet, shared the development of China's three major terminals and six major markets in 2015 and the 2016 forecast report; Li Jianhua, vice president of Kangmei Pharmaceutical Group, talked about the Internet + medical treatment on the tuyere On the evening of October 28, 2015, the annual figures of China's pharmaceutical economy were unveiled, and ten elites in the industry were honored Focusing on drug quality and innovation, the leaders of domestic drug enterprises held a closed door seminar with government officials and industry experts, and launched a heated and fruitful discussion At its parallel meeting, high-end dialogues were held on hot topics such as how e-commerce can break through and reconstruct the pharmaceutical logistics chain, and how pharmaceutical companies can lay out the era of precision medicine.